Get the Stockscreener App
10.15
3.05%
0.30
Relay Therapeutics Inc stock is traded at $10.15, with a volume of 2.66M.
It is up +3.05% in the last 24 hours and up +19.55% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
See More
Previous Close:
$9.85
Open:
$9.93
24h Volume:
2.66M
Relative Volume:
1.19
Market Cap:
$1.76B
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-3.625
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
+10.09%
1M Performance:
+19.55%
6M Performance:
+153.75%
1Y Performance:
+218.18%
1-Day Range:
$9.55
$10.25
1-Week Range:
$8.84
$11.43
52-Week Range:
$1.775
$11.43
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
10.15 | 1.71B | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 6%Should You Buy? - MarketBeat
Why Relay Therapeutics (RLAY) Is Up 14.8% After 2025 Beat, FDA Breakthrough Win for Zovegalisib - Sahm
Relay Therapeutics, Inc. (NASDAQ:RLAY) Sees Large Decrease in Short Interest - MarketBeat
Citizens reiterates Relay Therapeutics stock rating ahead of data By Investing.com - Investing.com Canada
Aug Levels: Is Relay Therapeutics Inc stock showing strong momentum2025 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
RLAYRelay Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Relay Therapeutics’ Promising Path with FDA Approvals and Revenue Growth - timothysykes.com
Bank Watch: What is the earnings history of Relay Therapeutics IncWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March - Sahm
Relay Therapeutics Surges After Breakthrough Designation for Breast Cancer Treatment - StocksToTrade
Relay Therapeutics’ Q4 Financial Performance Surges Amid Breakthrough Recognition - timothysykes.com
Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor Interest - Yahoo Finance
Relay Therapeutics stock hits 52-week high at 9.64 USD By Investing.com - Investing.com Canada
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million - AOL.com
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 61.57% Potential Upside in Precision Medicine - DirectorsTalk Interviews
RLAY: Wells Fargo Raises Price Target to $15, Maintains Overweig - GuruFocus
Wells Fargo & Company Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $15.00 - MarketBeat
RLAY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Relay Therapeutics Shares Jump 19% On Earnings And Pipeline Progress - Nasdaq
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week High on Strong Earnings - MarketBeat
Relay Therapeutics stock hits 52-week high at 9.64 USD - Investing.com
Decoding Relay Therapeutics Inc (RLAY): A Strategic SWOT Insight - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Announces Quarterly Earnings Results - MarketBeat
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones - Investing News Network
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Relay Therapeutics (RLAY) Surpasses Q4 Revenue Estimates, Eyes C - GuruFocus
Relay Therapeutics Q4 Loss Narrows, Revenue Rises; Cash Runway Into 2029 - marketscreener.com
Earnings Flash (RLAY) Relay Therapeutics Posts Q4 Loss Per Share $0.32, vs. FactSet Est of $0.40 Loss - marketscreener.com
Relay Therapeutics beats Q4 revenue expectations - TradingView
Relay Therapeutics Q4 Earnings Assessment - Benzinga
Relay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q4 Revenue $7.0M, vs. FactSet Est of $5.0M - marketscreener.com
Relay Therapeutics (NASDAQ: RLAY) narrows 2025 loss and sets major 2026 zovegalisib data milestones - Stock Titan
Cancer drug developer lines up 2026 trial milestones backed by $555M cash - Stock Titan
Relay Therapeutics earnings in spotlight after FDA breakthrough By Investing.com - Investing.com UK
Relay Therapeutics earnings in spotlight after FDA breakthrough - Investing.com
Private Capital Advisors Inc. Cuts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics Earnings Preview - Benzinga
Relay Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Investors get two chances to hear Relay Therapeutics in March - Stock Titan
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - The Motley Fool
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Could a 65.91% Upside Potential Spark Investor Interest? - DirectorsTalk Interviews
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 - The Manila Times
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - Quiver Quantitative
Precision medicine firm Relay Therapeutics sets Feb. 26 results release - Stock Titan
Investment Report: Is HEES stock suitable for long term investingPortfolio Risk Report & Low Risk Entry Point Tips - baoquankhu1.vn
Relay earnings in focus as FDA breakthrough fuels optimism By Investing.com - Investing.com Australia
Relay Therapeutics (RLAY) to Release Quarterly Earnings on Wednesday - MarketBeat
Casdin funds hold 13M Relay Therapeutics (RLAY) shares in passive stake - Stock Titan
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Trend Review: Will Relay Therapeutics Inc. benefit from government policyWeekly Investment Recap & AI Powered Market Entry Strategies - mfd.ru
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):